Abstract
Purpose
Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood—particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study’s aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors.
Methods
Participants (N = 515) with MBC were recruited from Dr. Susan Love Research Foundation’s Army of Women® and other advocacy organizations. Participants completed questionnaires of MBC-related collateral damage, depressive symptoms, anxiety, self-efficacy for managing oncologic treatments and physical symptoms, sleep, and physical activity.
Results
Eight domains of MBC-related collateral damage, as well as MBC-related benefit finding, were reliably characterized. Concerns about mortality/uncertainty were most prominent. Participants also endorsed high levels of benefit finding. Participants younger than 50 years, with limited financial resources, or with children under 18 at home reported the most collateral damage. Collateral damage was associated significantly with compromised psychological health, lower illness management efficacy, and poorer health behaviors, beyond sociodemographic and medical characteristics.
Conclusions
Subgroups of MBC patients report long-term, life-altering consequences of MBC and its treatments, which relate to important health outcomes. Clinical implications and recommendations are discussed.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Notes
One item included in the benefit finding subscale also loaded onto the self-concept disruption subscale at (− 0.44), which is weaker in magnitude than the other self-concept disruption item factor loadings. As such, this item was retained on the benefit finding subscale.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics (2018) CA Cancer J Clin 68(1):7–30
Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M (2017) Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809–815
Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V, Campone M et al (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734
Reed E, Simmonds P, Haviland J, Corner J (2012) Quality of life and experience of care in women with metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage 43(4):747–758
Slovacek L, Slovackova B, Slanska I, Petera J, Priester P (2010) Quality of life and depression among metastatic breast cancer patients. Med Oncol 27(3):958–959
Oh S, Heflin L, Meyerowitz BE, Desmond KA, Rowland JH, Ganz PA (2004) Quality of life of breast cancer survivors after a recurrence: a follow-up study. Breast Cancer Res Treat 87(1):45–57
Lewis S, Willis K, Yee J, Kilbreath S (2016) Living well? Strategies used by women living with metastatic breast cancer. Qual Health Res 26(9):1167–1179
Willis K, Lewis S, Ng F, Wilson L (2015) The experience of living with metastatic breast cancer-A review of the literature. Health Care Women Int 36(5):514–542
Ewertz M, Jensen AB (2011) Late effects of breast cancer treatment and potentials for rehabilitation. Acta Oncol 50(2):187–193
Lash TL, Thwin SS, Yood MU, Geiger AM, Bosco J, Quinn VP et al (2014) Comprehensive evaluation of the incidence of late effects in 5-year survivors of breast cancer. Breast Cancer Res Treat 144(3):643–663
Love SM, Bernstein L, Obidegwu O, Ottenbacher A, Eshraghi L, Clague J (2017) Collateral damage from metastatic breast cancer-preliminary results. Cancer Res.https://doi.org/10.1158/1538-7445.SABCS16-P4-20-03
Eshraghi L, Ortner HC, DeHart JNC, Stanton A, Williamson T, Jorge A et al (2017) Metastatic breast cancer collateral damage (MBCCD) project: think tank of advocates and provider-survivors. J Clin Oncol 35(31_suppl):55
Caplette-Gingras A, Savard J (2008) Depression in women with metastatic breast cancer: a review of the literature. Palliat Support Care 6(4):377–387
Low CA, Stanton AL (2015) Activity disruption and depressive symptoms in women living with metastatic breast cancer. Heal Psychol 34(1):89–92
Fulton CL (1997) The physical and psychological symptoms experienced by patients with metastatic breast cancer before death. Eur J Cancer Care 6(4):262–266
Jehn CF, Flath B, Strux A, Krebs M, Possinger K, Pezzutto A et al (2012) Influence of age, performance status, cancer activity, and IL-6 on anxiety and depression in patients with metastatic breast cancer. Breast Cancer Res Treat 136(3):789–794
Love AW, Grabsch B, Clarke DM, Bloch S, Kissane DW (2004) Screening for depression in women with metastatic breast cancer: a comparison of the Beck Depression Inventory short form and the Hospital Anxiety and Depression Scale. Aust N Z J Psychiatry 38(7):526–531
Meisel JL, Domchek SM, Vonderheide RH, Giobbie-Hurder A, Lin NU, Winer EP et al (2012) Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer 12(2):119–126
DiBonaventura MD, Copher R, Basurto E, Faria C, Lorenzo R (2014) Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Heal Drug Benefits 7(7):386–396
Hadji P, Ziller V, Kyvernitakis J, Schmidt N, Kostev K (2013) Persistence with bisphosphonates in patients with metastatic breast cancer: A retrospective database analysis. J Cancer Res Clin Oncol 139(7):1149–1155
Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry K et al (2016) Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2− metastatic breast cancer: a retrospective US claims study. Expert Opin Pharmacother 17(9):1189–1196
Güth U, Huang DJ, Schötzau A, Schmid SM (2016) Use of palliative endocrine therapy in patients with hormone receptor-positive distant metastatic breast cancer: How often, how effective, how long? Oncology 90(1):1–9
Koopman C, Nouriani B, Erickson V, Anupindi R, Butler LD, Bachmann MH et al (2002) Sleep disturbances in women with metastatic breast cancer. Breast J 8(6):362–370
Mosher CE, DuHamel KN (2012) An examination of distress, sleep, and fatigue in metastatic breast cancer patients. Psychooncology 21(1):100–107
Yee J, Davis GM, Beith JM, Wilcken N, Currow D, Emery J et al (2014) Physical activity and fitness in women with metastatic breast cancer. J Cancer Surviv 8(4):647–656
Hublin C, Partinen M, Koskenvuo M, Kaprio J (2007) Sleep and mortality: A population-based 22-year follow-up study. Sleep 30(10):1245–1253
Warburton DER, Nicol CW, Bredin SSD (2006) Health benefits of physical activity: the evidence. CMAJ 174(6):801–809
Rothrock NE, Kaiser KA, Cella D (2011) Developing a valid patient-reported outcome measure. Clin Pharmacol Ther 90(5):737–742
Brod M, Tesler LE, Christensen TL (2009) Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res 18(9):1263–1278
Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S et al (2010) The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol 63(11):1179–1194
Gruber-Baldini AL, Velozo C, Romero S, Shulman LM (2017) Validation of the PROMIS® measures of self-efficacy for managing chronic conditions. Qual Life Res 26(7):1915–1924
Jensen RE, King-Kallimanis BL, Sexton E, Reeve BB, Moinpour CM, Potosky AL et al (2016) Measurement properties of PROMIS sleep disturbance short forms in a large, ethnically diverse cancer cohort. Psychol Test Assess Model 58(2):353–370
Wagner LI, Schink J, Bass M, Patel S, Diaz MV, Rothrock N et al (2015) Bringing PROMIS to practice: brief and precise symptom screening in ambulatory cancer care. Cancer 121(6):927–934
Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D et al (2002) High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 13(7):625–635
Child D (1990) The essentials of factor analysis. Cassell Educational, London
Hu LT, Bentler PM (1995) Evaluating model fit. In: Hoyle RH (ed) Structural equation modeling: concepts, issues, and applications. Sage Publications, Thousand Oaks, pp 76–99
Wiley JF, Gruenewald TL, Karlamangla AS, Seeman TE (2016) Modeling multisystem physiological dysregulation. Psychosom Med 78(3):290–301
Peppercorn JM, Smith TJ, Helft PR, DeBono DJ, Berry SR, Wollins DS et al (2011) American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 29:755–760
Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith M, Lou SJ et al (2012) Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol 30(34):4249–4255
Cella DF, Tulsky DS, Gray G (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579
Howard-Anderson J, Ganz PA, Bower JE, Stanton AL (2012) Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst 104(5):386–405
Knobf MT (2006) The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist 11(2):96–110
Ashing-Giwa KT, Lim JW (2009) Examining the impact of socioeconomic status and socioecologic stress on physical and mental health quality of life among breast cancer survivors. Oncol Nurs Forum 36(1):79–88
Chino F, Peppercorn J, Taylor DH Jr, Lu Y, Samsa G, Abernethy AP et al (2014) Self-reported financial burden and satisfaction with care among patients with cancer. Oncologist 19(4):414–420
Schlegel RJ, Manning MA, Molix LA, Talley AE, Bettencourt BA (2012) Predictors of depressive symptoms among breast cancer patients during the first year post diagnosis. Psychol Health 27(3):277–293
Bloom JR, Stewart SL, Chang S, Banks PJ (2004) Then and now: quality of life of young breast cancer survivors. Psychooncology 13(3):147–160
DeShields T, Tibbs T, Fan MY, Taylor M (2006) Differences in patterns of depression after treatment for breast cancer. Psychooncology 15(5):398–406
Bright EE, Stanton AL (2018) Prospective investigation of social support, coping, and depressive symptoms: a model of adherence to endocrine therapy among women with breast cancer. J Consult Clin Psychol 86(3):242–253
Thornton LM, Andersen BL, Carson WE (2008) Immune, endocrine, and behavioral precursors to breast cancer recurrence: a case-control analysis. Cancer Immunol Immunother 57(10):1471–1481
Harvey AG (2002) Trouble in bed: the role of pre-sleep maintenance of insomnia. J Cogn Psychother 16(2):161–177
Harvey AG (2000) Pre-sleep cognitive activity: a comparison of sleep-onset insomniacs and good sleepers. Br J Clin Psychol 39(3):275–286
Yancey AK, Ortega AN, Kumanyika SK (2006) Effective recruitment and retention of minority research participants. Annu Rev Public Health 27(1):1–28
Acknowledgements
We are grateful to the women and men who participated in this research. We are grateful to our advocate task force, including Cecilia Alvear (in memoriam), Dikla Benzeevi, Virginia Empey, Beth Fairchild, Michael Kovarik, Sheila McGlown, Carol Miele, RN, B.S., MPH, Lori Marx Rubiner (in memoriam), Sandra Spivey, Lynn Tramonte, Patricia Wu, Ed.D., and others, for their dedication to this research. This research was supported in part by a National Institute of Mental Health Predoctoral Fellowship (Williamson, MH 15750), the Breast Cancer Research Foundation (Stanton), Pfizer, Avon Breast Cancer Crusade, Celgene, Genentech, and Lilly Oncology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This research complied with laws of the country in which it was performed. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Williamson, T.J., Love, S.M., Clague DeHart, J.N. et al. Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE). Breast Cancer Res Treat 171, 75–84 (2018). https://doi.org/10.1007/s10549-018-4823-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-018-4823-x